B+
Bull case
25%
Probability
Target price
$32.30
Analysis reference price unavailable
Analysis 2026-01-16 · RankAlpha Sentiment AI
NBTX
NanobiotixFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment AIMost likely
B
Base case
55%
Probability
Target price
$21.53
Analysis reference price unavailable
Analysis 2026-01-16 · RankAlpha Sentiment AI
B-
Bear case
20%
Probability
Target price
$8.61
Analysis reference price unavailable
Analysis 2026-01-16 · RankAlpha Sentiment AI
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-01-16
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+10.6
Score
AI commentary
Market sentiment is mixed: third-party targets show high dispersion, producing headline-driven volatility. Commentary centers on binary clinical/regulatory outcomes with wide near-term estimate divergence [#SERP-1][#SERP-2][#SERP-3].
RankAlpha Sentiment AI - 2026-01-16
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-04-16catalystAnalyst updates / consensus revisionsHigh impact
Wide published target dispersion may trigger analyst revisions and headline volatility; used published ranges as a sanity check [#SERP-1][#SERP-2].
2027-01-16eventPivotal clinical readout for lead radiotherapy asset (estimated)High impact
No firm public date disclosed; conservatively estimated within 12 months. A binary clinical outcome could drive a material re-rating [#SERP-3].
2027-01-16catalystRegulatory / commercialization milestonesHigh impact
Regulatory filing/approval or early commercialization would be value-accretive but is low probability within 12 months absent positive clinical data [#SERP-2][#SERP-4].
Recommendation
N/A
No formal recommendation provided.
As of 2026-01-16 • Updated nightlySource: Internal modelMethodology